A GLP-1 medication can make you more likely to get pregnant — and these drugs are not considered safe to take during pregnancy. Weight loss and improved insulin sensitivity on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can restart ovulation that obesity or PCOS had switched off, so pregnancy can happen sooner than expected. Because the FDA labels advise stopping before conception and animal studies show possible fetal harm, the safest approach is deliberate: reliable contraception if you don't want to conceive now, and a clinician-guided pause before you do. If you think you might be pregnant on a GLP-1, contact your clinician promptly.
Three separate truths collide here, and most thin online explainers only tell you one of them. Fertility can go up. The drug is not safe once you are pregnant. And your birth control may quietly become less reliable at the same time. Understanding all three is how you avoid a surprise — in either direction. (New to these medicines? Start with GLP-1s explained.)
Can a GLP-1 actually make you more fertile?
Indirectly, yes — and this is the real engine behind the "Ozempic baby" headlines. GLP-1 receptor agonists are not fertility drugs and none is FDA-approved to treat infertility or induce ovulation. But two of their well-documented effects — meaningful weight loss and improved insulin sensitivity — are exactly what can restart ovulation in women whose cycles had stopped.
In obesity and in PCOS-related insulin resistance, excess weight and high insulin disrupt the hormonal signals that trigger ovulation, which is why periods can become irregular or absent. Even modest weight loss can rebalance those signals and bring ovulation back. So a woman who assumed she couldn't easily conceive — perhaps for years — can start ovulating within months of beginning treatment, often before she notices any change in her cycle. An Australian cohort study of reproductive-age women starting GLP-1s found that fewer than one in four were using contraception when they began, and a meaningful share became pregnant within six months. Restored fertility is a genuine benefit if pregnancy is the goal; it is a trap if it isn't.
Are GLP-1s safe during pregnancy?
No — they are not considered safe, and the labels are clear that weight loss offers no benefit during pregnancy and may cause harm. In animal reproduction studies, semaglutide given during organogenesis caused embryofetal death, structural abnormalities, and growth changes at exposures below the maximum human dose. Tirzepatide's animal data showed similar developmental and growth effects. Human data are limited and emerging: early reports, including a study of 168 pregnancies exposed to GLP-1s (51 on semaglutide), have not so far flagged an increased rate of major birth defects. That is reassuring but is not proof of safety — the numbers are small, and "no signal yet" is not the same as "safe."
Because of this, the FDA label for semaglutide (Wegovy) advises discontinuing the drug at least 2 months before a planned pregnancy — a buffer built around its long half-life of roughly one week, meaning it takes about five to seven weeks to clear. If pregnancy is recognized while taking it, the label says to stop. Tirzepatide has a shorter half-life of about 5 days, and its label likewise advises stopping when pregnancy is recognized; your clinician will decide how far ahead of conception to pause it. These are the labels' words and your prescriber's call — not timing you should improvise. If you are weighing a stop, read what happens when you stop a GLP-1 and plan it as a conversation, not a guess.
The contraception trap: how "Ozempic babies" really happen
Two things stack up. First, fertility can return before you expect it. Second — and this is the part most pages get wrong — one of these drugs can make the pill less reliable, and it is not the one most people assume.
Tirzepatide (Mounjaro, Zepbound) slows stomach emptying enough to reduce how much of an oral contraceptive gets absorbed. Its FDA label reports that peak blood levels of the pill's estrogen component (ethinyl estradiol) fell by about 59% after the first dose, with the progestin components similarly reduced. The effect is largest right after starting and after each dose increase. So the label advises women on oral hormonal contraception to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation. Non-oral methods — the IUD, implant, injection, patch, or ring — are not affected by delayed stomach emptying.
Semaglutide (Ozempic, Wegovy, Rybelsus) does not carry this warning. A dedicated interaction study found it did not meaningfully reduce oral-contraceptive levels, and the label states no dose adjustment is needed and that it is not expected to lower the pill's effectiveness. Getting this distinction right matters: assuming semaglutide breaks your birth control, or assuming tirzepatide doesn't, are opposite mistakes. If you want a method that sidesteps the issue entirely, review non-hormonal birth control options, and see how tirzepatide works for the full picture.
The final ingredient in a surprise pregnancy is a reasonable-sounding assumption: "I had trouble conceiving before, so I don't really need contraception." On a GLP-1 that logic can quietly reverse — the drug may be treating the very thing that was reducing your fertility.
| Your situation | What to know | Discuss with your clinician |
|---|---|---|
| You want to get pregnant soon | The label advises stopping before conception (semaglutide: at least 2 months ahead; tirzepatide: timed by your clinician to its ~5-day half-life). Reaching a healthier weight first can genuinely help. | A planned pause, folic acid and preconception care, and how long to wait after your last dose. |
| You don't want to be pregnant right now | A GLP-1 can restart ovulation even if your periods were irregular or absent — sometimes before you notice. | Reliable contraception in place before or as you start; if you take the pill and start tirzepatide, a non-oral method or added barrier per the label. |
| You just started tirzepatide (or raised the dose) and take the pill | Pill absorption drops most after the first dose and after each increase. | Switching to a non-oral method or adding a barrier method for 4 weeks, as the label advises. |
| You think you might be pregnant on a GLP-1 | Not considered safe in pregnancy. Don't panic — early human data are limited but not alarming — but act promptly. | Stopping the drug, a pregnancy test, next steps, and enrolling in the manufacturer's pregnancy registry. |
What about breastfeeding on a GLP-1?
Here the honest answer is "we don't have enough data, so it is generally not recommended and is a decision to make with your clinician." Human information is limited. In a small study of eight breastfeeding women, injectable semaglutide was not detected in breast milk, and tirzepatide transfer into milk has measured as negligible in the samples studied — both reassuring signals. But the oral tablet form of semaglutide (Rybelsus) is specifically not advised during breastfeeding, and small studies cannot rule out effects on a nursing infant. Because these drugs also drive weight loss and reduced appetite in the parent, adequate nutrition while nursing is a separate consideration. Treat breastfeeding as a case-by-case conversation, not a settled yes or no.
Is losing weight before pregnancy a good thing?
This is the nuance that gets lost. Being at a healthier weight before you conceive has real, well-established benefits — lower risks of gestational diabetes, high blood pressure in pregnancy, and cesarean delivery, among others. An emerging 2025 analysis even linked preconception GLP-1 use with lower rates of some adverse obstetric outcomes. The problem was never the weight loss beforehand. The problem is the drug being on board during and immediately around pregnancy. That is precisely why the plan for many women is: use the medication to reach a healthier weight, then pause it on your clinician's schedule before trying to conceive — capturing the benefit of the weight change without exposing a pregnancy to the drug. Obesity and PCOS are chronic, clinician-managed conditions, so also talk through how you'll maintain progress during any pause and after pregnancy.
What about "microdosing," compounded shots, or GLP-1s "for fertility"?
Marketing has raced ahead of the evidence. No GLP-1 is approved to treat infertility, and "microdosing" for fertility or longevity is not a studied or validated use. Compounded and grey-market GLP-1s bought online carry added uncertainty about dose, purity, and what's actually in the vial — a poor foundation for anything involving a possible pregnancy. If you are considering these medicines, do it through a legitimate prescriber; our guide to getting a GLP-1 online safely covers the red flags, and the cost and coverage estimator can help you weigh legitimate options. For PCOS-related infertility specifically, evidence-based paths — structured weight management, ovulation induction, and metformin — belong in the conversation.
When to see a doctor
Talk with a clinician before starting or stopping a GLP-1 if you could become pregnant — every start, stop, dose change, and contraceptive choice here is prescriber-led. Beyond routine planning, contact your clinician promptly if:
- You think you might be pregnant while on a GLP-1. This is the priority red flag. Don't panic and don't stop other prescribed medicines on your own — call your clinician, take a pregnancy test, and follow their guidance on stopping the drug and next steps.
- You have a possible birth-control failure — a missed pill during the first weeks of tirzepatide or after a dose increase, or vomiting that could have reduced absorption.
- Your periods return or change after starting a GLP-1, which can be an early sign that ovulation has resumed.
- You are planning a pregnancy and want to time a washout, start folic acid, and arrange preconception care.
Seek urgent or emergency care for severe or persistent abdominal pain (which can radiate to the back and may signal pancreatitis), or for signs of a possible ectopic pregnancy such as sharp one-sided pelvic pain, shoulder-tip pain, dizziness, or unusual bleeding. When in doubt about a symptom on a GLP-1, it is always reasonable to call.
This article is a reference to help you have a better conversation with a qualified clinician. It is not medical advice, and it does not tell anyone to start, stop, switch, or dose any medication or contraceptive — those decisions are made with your prescriber, guided by the current FDA label and your own health history.
